Skip to content

Calculus fully exit Genedrive plc for an average ROI of 2.1x

Calculus has delivered an average ROI of 2.1x from Genedrive plc (AIM: GDR) through a number of exits in the VCT and EIS Funds. Genedrive, a company we had supported through scale-up, was founded as a contract research business (”CRO”) but refocussed as a Point of Care molecular diagnostics company. The company has developed and launched … Continued

Q1 2022 Update

Welcome to our first update of 2022. The run up to the tax year end is always a busy time and this year has been no different. Our investment team has completed two exits, three investments and are building up a considerable pipeline for Q2. As popularity for VCTs across the board has continued to … Continued

Calculus invests in Destiny Pharma

Calculus VCT has invested into Destiny Pharma, a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention.

Read more